New drug combo aims to stop prostate Cancer's return
NCT ID NCT07282197
Summary
This study is testing if adding a newer drug called darolutamide to standard hormone therapy (ADT) can better prevent prostate cancer from returning after surgery. It will involve about 40 men who had surgery for high-risk prostate cancer but did not have extensive lymph node removal. Researchers will track if the cancer comes back over two years and monitor the treatment's side effects and impact on quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.